An investigational vaccine appears generally well tolerated and effective against the most common strain of norovirus, reducing the main symptoms of the gastrointestinal infection, vomiting and/or diarrhea, by 52 percent.
An investigational vaccine appears generally well tolerated and effective against the most common strain of norovirus, reducing the main symptoms of the gastrointestinal infection, vomiting and/or diarrhea, by 52 percent.